ProCE Banner Activity

Phase III MAINTAIN: Extended Rituximab Maintenance in Follicular Lymphoma After First-line Bendamustine + Rituximab

Slideset Download
Conference Coverage
In patients with FL treated with BR induction therapy, 4 years vs 2 years of rituximab maintenance appears to improve PFS.

Released: December 20, 2017

Share

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

This activity is supported by educational grants from

AbbVie

AstraZeneca

Celgene

Genentech TEXT Only

Janssen Biotech Pharmacyclics Abbvie

Jazz Pharmaceuticals Inc

Novartis Pharmaceuticals Corporation

Pharmacyclics Inc

Seagen

Takeda Oncology